Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00106366

Enrollment

389

Registered

2005-03-23

Start date

2005-03-31

Completion date

2005-12-31

Last updated

2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Keywords

Diabetes, Type 2

Brief summary

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Interventions

DRUGinsulin detemir

DRUGinsulin glargine

DRUGinsulin aspart

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes for more than 12 months * Currently treated with glucose lowering tablets or insulin * HbA1c: 7.0-12.0%

Design outcomes

Primary

Measure	Time frame
HbA1c	after 26 weeks

Secondary

Measure	Time frame
Body weight	—
Glucose profiles	—

Countries

Canada, Puerto Rico, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026